Comparison of Galapagos NV (GLPG) and Ardelyx Inc. (NASDAQ:ARDX)

As Biotechnology companies, Galapagos NV (NASDAQ:GLPG) and Ardelyx Inc. (NASDAQ:ARDX) are our subject to contrast. And more specifically their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Galapagos NV N/A 0.00 N/A -1.69 0.00
Ardelyx Inc. 44.52M 3.63 53.32M -0.96 0.00

In table 1 we can see Galapagos NV and Ardelyx Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Galapagos NV 0.00% 0% 0%
Ardelyx Inc. -119.77% -37.2% -29%

Analyst Recommendations

The Recommendations and Ratings for Galapagos NV and Ardelyx Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Galapagos NV 0 0 6 3.00
Ardelyx Inc. 0 0 1 3.00

$126.5 is Galapagos NV’s consensus price target while its potential upside is 23.70%. Ardelyx Inc. on the other hand boasts of a $7 consensus price target and a 169.23% potential upside. Based on the analysts belief we can conclude, Ardelyx Inc. is looking more favorable than Galapagos NV.

Insider & Institutional Ownership

The shares of both Galapagos NV and Ardelyx Inc. are owned by institutional investors at 19.34% and 85.2% respectively. Comparatively, insiders own roughly 1.4% of Ardelyx Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Galapagos NV 1.58% -6.19% 5.07% 0.46% 20.27% 9.12%
Ardelyx Inc. -10.29% -28.86% -35.79% -39.75% -58.99% -63.03%

For the past year Galapagos NV has 9.12% stronger performance while Ardelyx Inc. has -63.03% weaker performance.

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The companyÂ’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, CrohnÂ’s disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis (AtD) patients in Phase Ib trial. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. It also has a research and development agreement with Pharnext SA to develop a pipeline of synergistic drug combinations for various indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.